Biotech entity
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 2 also mention Axon Enterprise, the most common co-covered peer. They are better corroborated than the beat average, carrying 5 original sources each against 3.3 for the same window.
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 2 also mention Axon Enterprise, the most common co-covered peer. They are better corroborated than the beat average, carrying 5 original sources each against 3.3 for the same window. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Supernus Pharmaceuticals appears in 2 tracked Biotech stories published from February 23, 2026 through February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 58 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Supernus Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.
Supernus Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
